Floatz logo

Irinotecan

Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma

City of Hope Medical CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Fludarabine
Marcela V. Maus, M.D.,Ph.D.
Phase 2B
Anakinra
M.D. Anderson Cancer Center
Phase 2B
Vorinostat
City of Hope Medical Center
Phase 1CC
Autologous Cd19-Cd8-Cd28-Cd3Zeta-Car-Mbil15-Her1T T Cells
M.D. Anderson Cancer Center
Phase 1CC
FAZA
University of California, San Francisco
D

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →